Zimbabwe has declined a significant US healthcare agreement worth $367m (£272m) over five years because of Washington's demand for sensitive biological samples.
This move came to light following a government memo dated December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
A government spokesman has since explained that the US was seeking biological samples for research and commercial purposes but refused to guarantee the resulting advantages from any future treatments.
"We must now begin the challenging and unfortunate process of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for further talks to reach a deal agreeable to both sides so the country's vital HIV programme can proceed.
Broader Context
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a court blocked a similar health funding agreement after concerns were raised about the security of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had administered assistance for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking direct bilateral deals to enhance transparency and accountability.
According to statements, Sixteen African countries have so far agreed to these new health pacts, representing over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation might have yielded extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to share its biological resources and data for a long time, without any corresponding guarantee of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"In essence, our country would supply the raw materials for scientific discovery without any assurance that the final treatments would be available to our population if a future disease outbreak arise."
National Interest and International Frameworks
Mangwana further noted that the American exit from the global health body and its push of one-on-one health agreements were undermining frameworks previously set up through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing system designed to manage future pandemics.
"This framework is designed to ensure that when a nation provides its data, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to create them."
These objections over the US deal "are not meant as opposition to America," he added.
"We are open to continued discussions with our American counterparts on how future collaboration might be arranged in a manner that respects the sovereignty and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but urged that negotiations need to persist considering much of the country's Aids initiatives depended on external financing.
"If technical issues arise, including those involving information security or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," the group commented.
This impasse emphasises the complex tensions between receiving vital international aid and safeguarding local interests in an increasingly data-driven world.